Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 11Obesity 4Sarcopenia 3Polycystic Ovary Syndrome 3Neoplasms 3Melanoma 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Malnutrition 2Lymphoma, Follicular 2Colorectal Neoplasms 2Breast Carcinoma In Situ 2Wound Infection 1Weight Loss 1Urinary Bladder Neoplasms 1Surgical Wound Infection 1Stomach Neoplasms 1Smoldering Multiple Myeloma 1Skin Neoplasms 1Psoriasis 1Precancerous Conditions 1Postoperative Complications 1Polyps 1Phagocyte Bactericidal Dysfunction 1Pain 1Paget's Disease, Mammary 1Overweight 1Osteoarthritis 1Olfaction Disorders 1Non-alcoholic Fatty Liver Disease 1

Interventions

Sorafenib 68Bevacizumab 44Oxaliplatin 25Doxorubicin 22Gemcitabine 21Fluorouracil 21Radiosurgery 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17lenvatinib 17Cisplatin 17Capecitabine 17atezolizumab 14Leucovorin 14Hepatectomy 14Radiotherapy 12tremelimumab 10Irinotecan 10Drug Therapy 10Cyclophosphamide 10Carboplatin 10Blood Specimen Collection 10Ipilimumab 9regorafenib 8Liver Transplantation 8Everolimus 8Cryosurgery 8Chemotherapy, Adjuvant 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × Docosahexaenoic Acids × Clear all
NCT00422877 2025-10-16

Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract

American Regent, Inc.

Phase 2 Terminated
13 enrolled
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡